Cargando…
ET-6 Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
BACKGROUND: Malignant meningioma is an aggressive tumor that requires adjuvant radiotherapy after surgery, yet there has been no standard systemic therapy established so far. We have demonstrated that malignant meningioma cells are exquisitely sensitive to gemcitabine due to their increased expressi...
Autores principales: | Yamamoto, Masahiro, Kitanaka, Chifumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648159/ http://dx.doi.org/10.1093/noajnl/vdab159.016 |
Ejemplares similares
-
Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021) -
ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021) -
Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins
por: Yamamoto, Masahiro, et al.
Publicado: (2022) -
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021) -
Galacto‐conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity
por: González‐Gualda, Estela, et al.
Publicado: (2020)